Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Joseph Cuppari

Vascular Surgery Clinton Township, MI Doctor of Osteopathy

NPI 1538470067 CMS profile 341760

37400 Garfield Rd Ste 120, Clinton Township, MI 48036

Open in the dashboard

General payments

$97,869

450 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Joseph Cuppari of Clinton Township, MI is reported in the CMS Open Payments database as having received $97,869 across 450 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Vascular Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,330 80
2024 General $6,036 71
2023 General $10,073 60
2022 General $11,903 52
2021 General $17,055 67
2020 General $16,375 54
2019 General $32,097 66

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Joseph Cuppari
  • Vascular Surgery median
  • Middle half of Vascular Surgery
  • National median

In program year 2025, general payments to Joseph Cuppari were reported at $4,330. Among 3,991 Vascular Surgery profiles paid that year, the median was $924 and the middle half received between $273 and $2,636.

Show as a table
Year Joseph Cuppari Vascular Surgery median Middle half National median
2019 $32,097 $796 $226–$2,363 $163
2020 $16,375 $348 $118–$1,110 $114
2021 $17,055 $471 $158–$1,421 $132
2022 $11,903 $725 $222–$2,183 $149
2023 $10,073 $836 $257–$2,440 $160
2024 $6,036 $909 $252–$2,619 $164
2025 $4,330 $924 $273–$2,636 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Endologix, Inc. $77,791 151 payments
  2. Intuitive Surgical, Inc. $5,769 14 payments
  3. Bard Peripheral Vascular, Inc. $3,868 60 payments
  4. Organogenesis Inc. $2,261 62 payments
  5. LeMaitre Vascular, Inc. $1,212 14 payments
  6. Medtronic Vascular, Inc. $1,128 12 payments
  7. Stryker Corporation $1,104 7 payments
  8. Silk Road Medical, Inc. $824 9 payments
  9. Kerecis Limited $663 19 payments
  10. Inari Medical, Inc. $616 27 payments
  11. Other $2,632 75 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $69,738 54 payments
  2. Food and Beverage $20,076 375 payments
  3. Travel and Lodging $4,036 19 payments
  4. Education $4,019 2 payments
Products named General payments · program years 2019–2025
  1. Ovation $36,022 57 payments
  2. Alto Abdominal Stent Graft System $26,255 64 payments
  3. AFX $14,029 12 payments
  4. AFX2 Bifurcated Endograft System $5,156 5 payments
  5. Da Vinci Surgical System Surgery $4,000 1 payment
  6. Da Vinci Surgical System Surgery $1,769 13 payments
  7. ENDOCROSS Device $1,549 12 payments
  8. Torus Stent Graft System $1,549 12 payments
  9. N/A $1,001 3 payments
  10. Endurant $972 9 payments
  11. Other $13,932 347 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 6 drugs

Part D claims

230

Median for General Surgery: 59

Drug cost

$63,766

Median for General Surgery: $393

Branded share of claims

74.8%

Median for General Surgery: 28.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xarelto Rivaroxaban Brand 38 $33,153
Eliquis Apixaban Brand 24 $27,001
Clopidogrel Clopidogrel Bisulfate Brand 110 $2,022
Cilostazol Generic 31 $1,193
Gabapentin Generic 15 $283
Atorvastatin Calcium Generic 12 $113

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 15,891 Part D prescribers listed as General Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 136 billing codes

Paid by Medicare

$178,262

Medicare's payments for the services billed

Medicare patients

557

Average age 75

Services billed

1,671

273 women, 284 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 54%
Arthritis 51%
Diabetes 46%
Chronic kidney disease 44%
COPD 43%
Heart failure 37%
Atrial fibrillation 35%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

450 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular Surgery in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record